

Taigo Kato

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6549752/publications.pdf>

Version: 2024-02-01

56
papers

1,308
citations

331259

21
h-index

395343

33
g-index

58
all docs

58
docs citations

58
times ranked

1933
citing authors

#	ARTICLE	IF	CITATIONS
1	A case of perirenal non-specific lymphadenitis mimicking a solitary renal mass. IJU Case Reports, 2022, 5, 10-13.	0.1	1
2	Editorial Comment from Dr. Kato to Recurrent urinary retention due to clots caused by a congenital renal arteriovenous malformation that forms a complex vascular network: Report of two cases. IJU Case Reports, 2022, 5, 8-9.	0.1	0
3	Everolimus Reduces Cancer Incidence and Improves Patient and Graft Survival Rates after Kidney Transplantation: A Multi-Center Study. Journal of Clinical Medicine, 2022, 11, 249.	1.0	3
4	CCR8-targeted specific depletion of clonally expanded Treg cells in tumor tissues evokes potent tumor immunity with long-lasting memory. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, .	3.3	68
5	Early dynamics of circulating tumor DNA predict clinical response to immune checkpoint inhibitors in metastatic renal cell carcinoma. International Journal of Urology, 2022, 29, 462-469.	0.5	6
6	Perioperative circulating tumor DNA enables the identification of patients with poor prognosis in upper tract urothelial carcinoma. Cancer Science, 2022, 113, 1830-1842.	1.7	11
7	Incidence and mortality of post-transplant lymphoproliferative disorders after kidney transplantation: A real-world retrospective analysis in Japan. International Journal of Urology, 2022, 29, 206-211.	0.5	1
8	High-fat diet promotes prostate cancer growth through histamine signaling. International Journal of Cancer, 2022, 151, 623-636.	2.3	12
9	Editorial Comment to Determining programmed cell death ligand 1 expression in circulating tumor cells of patients with clear cell renal cell carcinoma and its correlation with response to programmed cell death protein 1 inhibitors. International Journal of Urology, 2022, 29, 954-955.	0.5	0
10	Trop-2 in Upper Tract Urothelial Carcinoma. Current Oncology, 2022, 29, 3911-3921.	0.9	13
11	Circulating extracellular vesicles carrying Firmicutes reflective of the local immune status may predict clinical response to pembrolizumab in urothelial carcinoma patients. Cancer Immunology, Immunotherapy, 2022, 71, 2999-3011.	2.0	4
12	Real-world efficacy and safety of nivolumab plus ipilimumab in untreated metastatic renal cell carcinoma, and the impact of previous nephrectomy on clinical outcome: Japanese multi-institutional retrospective study. International Journal of Clinical Oncology, 2022, 27, 1596-1604.	1.0	11
13	Cumulative cancer incidence and mortality after kidney transplantation in Japan: A long-term multicenter cohort study. Cancer Medicine, 2021, 10, 2205-2215.	1.3	15
14	Successful recovery from coronavirus disease 2019 in a living kidney transplant recipient using low-dose methylprednisolone. IJU Case Reports, 2021, 4, 22-24.	0.1	6
15	Fragmentation of cell-free DNA is induced by upper tract urothelial carcinoma-associated systemic inflammation. Cancer Science, 2021, 112, 168-177.	1.7	6
16	Peripheral T cell receptor repertoire features predict durable responses to anti-PD-1 inhibitor monotherapy in advanced renal cell carcinoma. OncoImmunology, 2021, 10, 1862948.	2.1	20
17	Therapeutic and Clinical Outcomes of Robot-assisted Partial Nephrectomy versus Cryoablation for T1 Renal Cell Carcinoma. In Vivo, 2021, 35, 1573-1579.	0.6	9
18	Proteomic analysis of urinary and tissue-exudative extracellular vesicles to discover novel bladder cancer biomarkers. Cancer Science, 2021, 112, 2033-2045.	1.7	35

#	ARTICLE	IF	CITATIONS
19	Durable response of chemotherapy for cancer of unknown primary with unfavorable subset developed in retroperitoneal space. <i>IJU Case Reports</i> , 2021, 4, 255-258.	0.1	0
20	Gut Microbiotaâ€‘Derived Short-Chain Fatty Acids Promote Prostate Cancer Growth via IGF1 Signaling. <i>Cancer Research</i> , 2021, 81, 4014-4026.	0.4	83
21	The prognostic impact of immune-related adverse events in metastatic renal cell carcinoma patients treated with nivolumab: a real-world multi-institutional retrospective study. <i>International Journal of Clinical Oncology</i> , 2021, 26, 954-961.	1.0	9
22	Real-world Outcomes of Tyrosine Kinase Inhibitors Immediately After Immune Checkpoint Inhibitors in Renal Cell Carcinoma. <i>Anticancer Research</i> , 2021, 41, 5811-5816.	0.5	4
23	Expression of Nectin-4 and PD-L1 in Upper Tract Urothelial Carcinoma. <i>International Journal of Molecular Sciences</i> , 2020, 21, 5390.	1.8	48
24	A Potential Mechanism of Anticancer Immune Response Coincident With Immune-related Adverse Events in Patients With Renal Cell Carcinoma. <i>Anticancer Research</i> , 2020, 40, 4875-4883.	0.5	6
25	Resumption of antiâ€‘programmed cell death 1 monotherapy for severe immuneâ€‘related adverse events experienced patient with renal cell carcinoma. <i>IJU Case Reports</i> , 2020, 3, 176-179.	0.1	1
26	Efficacy of a Si-based agent against developing renal failure in a rat remnant kidney model. <i>Biochemical and Biophysical Research Communications</i> , 2020, 533, 698-703.	1.0	4
27	<p>Clinical Efficacy of Intravenous Immunoglobulin for BK Polyomavirus-Associated Nephropathy After Living Kidney Transplantation</p>. <i>Therapeutics and Clinical Risk Management</i> , 2020, Volume 16, 947-952.	0.9	11
28	Intratumoral and s.c. injection of inactivated hemagglutinating virus of Japan envelope (GEN0101) in metastatic castrationâ€‘resistant prostate cancer. <i>Cancer Science</i> , 2020, 111, 1692-1698.	1.7	12
29	MicroRNAâ€‘92bâ€‘3p is a prognostic oncomiR that targets <i>TSC1</i> in clear cell renal cell carcinoma. <i>Cancer Science</i> , 2020, 111, 1146-1155.	1.7	19
30	The role of actinin-4 (ACTN4) in exosomes as a potential novel therapeutic target in castration-resistant prostate cancer. <i>Biochemical and Biophysical Research Communications</i> , 2020, 523, 588-594.	1.0	28
31	Clinical importance of the expression of CD4+CD8+ T cells in renal cell carcinoma. <i>International Immunology</i> , 2020, 32, 347-357.	1.8	10
32	Oral Administration of Si-Based Agent Attenuates Oxidative Stress and Ischemia-Reperfusion Injury in a Rat Model: A Novel Hydrogen Administration Method. <i>Frontiers in Medicine</i> , 2020, 7, 95.	1.2	15
33	Tumour grade significantly correlates with total dysfunction of tumour tissue-infiltrating lymphocytes in renal cell carcinoma. <i>Scientific Reports</i> , 2020, 10, 6220.	1.6	25
34	Leukocyteâ€‘associated immunoglobulinâ€‘like receptor γ 2/1 promotes tumorigenesis in RCC. <i>Oncology Reports</i> , 2019, 41, 1293-1303.	1.2	16
35	Results of weekday-on and weekend-off administration schedule of sunitinib therapy for advanced renal cell carcinoma. <i>International Journal of Clinical Oncology</i> , 2019, 24, 78-86.	1.0	3
36	Clinical significance of the mutational landscape and fragmentation of circulating tumor DNA in renal cell carcinoma. <i>Cancer Science</i> , 2019, 110, 617-628.	1.7	61

#	ARTICLE	IF	CITATIONS
37	TCR sequencing analysis of cancer tissues and tumor draining lymph nodes in colorectal cancer patients. <i>Oncolimmunology</i> , 2019, 8, e1588085.	2.1	17
38	Diagnostic potential of <i>TERT</i> promoter and <i>FGFR3</i> mutations in urinary cell-free DNA in upper tract urothelial carcinoma. <i>Cancer Science</i> , 2019, 110, 1771-1779.	1.7	63
39	Identification of neoantigen-specific T cells and their targets: implications for immunotherapy of head and neck squamous cell carcinoma. <i>Oncolimmunology</i> , 2019, 8, e1568813.	2.1	31
40	Phenotypic Analysis of Tumor Tissue-Infiltrating Lymphocytes in Tumor Microenvironment of Bladder Cancer and Upper Urinary Tract Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2019, 17, 114-124.	0.9	8
41	Induction of Neoantigen-Specific Cytotoxic T Cells and Construction of T-cell Receptor-Engineered T Cells for Ovarian Cancer. <i>Clinical Cancer Research</i> , 2018, 24, 5357-5367.	3.2	70
42	Effective screening of T cells recognizing neoantigens and construction of T-cell receptor-engineered T cells. <i>Oncotarget</i> , 2018, 9, 11009-11019.	0.8	44
43	The era of immunogenomics/immunopharmacogenomics. <i>Journal of Human Genetics</i> , 2018, 63, 865-875.	1.1	15
44	Similarity and difference in tumor-infiltrating lymphocytes in original tumor tissues and those of <i>in vitro</i> expanded populations in head and neck cancer. <i>Oncotarget</i> , 2018, 9, 3805-3814.	0.8	6
45	A pilot study of durvalumab and tremelimumab and immunogenomic dynamics in metastatic breast cancer. <i>Oncotarget</i> , 2018, 9, 18985-18996.	0.8	83
46	Increased level and fragmentation of plasma circulating cell-free DNA are diagnostic and prognostic markers for renal cell carcinoma. <i>Oncotarget</i> , 2018, 9, 20467-20475.	0.8	38
47	Characterization of the cryoablation-induced immune response in kidney cancer patients. <i>Oncolimmunology</i> , 2017, 6, e1326441.	2.1	34
48	<i>TOPK</i> (TAK1 cell-originated protein kinase) inhibitor exhibits growth suppressive effect on small cell lung cancer. <i>Cancer Science</i> , 2017, 108, 488-496.	1.7	28
49	p53-independent p21 induction by MELK inhibition. <i>Oncotarget</i> , 2017, 8, 57938-57947.	0.8	35
50	Integrated analysis of somatic mutations and immune microenvironment of multiple regions in breast cancers. <i>Oncotarget</i> , 2017, 8, 62029-62038.	0.8	28
51	Morphological Changes, Cadherin Switching, and Growth Suppression in Pancreatic Cancer by GALNT6 Knockdown. <i>Neoplasia</i> , 2016, 18, 265-272.	2.3	27
52	The benefits of cancer screening in kidney transplant recipients: a single-center experience. <i>Cancer Medicine</i> , 2016, 5, 153-158.	1.3	18
53	T-LAK Cell-Originated Protein Kinase (TOPK) as a Prognostic Factor and a Potential Therapeutic Target in Ovarian Cancer. <i>Clinical Cancer Research</i> , 2016, 22, 6110-6117.	3.2	63
54	Germline PARP4 mutations in patients with primary thyroid and breast cancers. <i>Endocrine-Related Cancer</i> , 2016, 23, 171-179.	1.6	39

#	ARTICLE	IF	CITATIONS
55	Effective growth-suppressive activity of maternal embryonic leucine-zipper kinase (MELK) inhibitor against small cell lung cancer. <i>Oncotarget</i> , 2016, 7, 13621-13633.	0.8	41
56	Oncogenic roles of TOPK and MELK, and effective growth suppression by small molecular inhibitors in kidney cancer cells. <i>Oncotarget</i> , 2016, 7, 17652-17664.	0.8	44